Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today ...

BOSTON, Jan. 13, 2026 (GLOBE NEWSWIRE) -- (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today announced the appointment of ...

I am a few years out of a long, vanilla marriage. I’ve always had an interest in kink and BDSM, but my ex was not interested ...

At Praxis, Dr. Devinsky will be part of the group leading clinical strategy and global medical affairs, guiding program architecture, evidence generation, and external scientific engagement as the ...

My goal is to bring great taste back to America... and we are doing this every day-- with Hangry Spice!”— Michael ...

Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for ...

“Megan’s leadership has been a significant driver of Praxis’s success to date,” said Mr. Souza. “As COO, she is uniquely positioned to guide Praxis through its next phase, driving disciplined ...

BOSTON, Jan. 08, 2026 (GLOBE NEWSWIRE) -- (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) ...

For me, the most significant experience of the social, political and cultural movement emerging from the struggles culminating in ’68 and, even more so in ’69 (the working-class “hot autumn”!) was ...

Having already claimed a win for the phase 2 study of its seizure drug, Praxis Precision Medicines is hoping fresh efficacy data will form the backbone of an approval application for the sodium ...

Praxis Precision Medicines has also announced a “successful” pre-NDA meeting with the FDA for its essential tremor drug candidate ulixacaltamide, for which an approval application is slated for early ...

Today, a brief rundown of news from Praxis Precision Medicines and Bristol Myers Squibb, as well as updates from Denali Therapeutics, Crescent Biopharma and AstraZeneca that you may have missed.